Journal
VIRUSES-BASEL
Volume 14, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/v14050912
Keywords
respiratory syncytial virus (RSV); antiviral; prophylactic; therapeutic
Categories
Funding
- Georgia Research Alliance
Ask authors/readers for more resources
This study investigated the prophylactic and therapeutic efficacy of probenecid, an FDA-approved drug, in inhibiting RSV replication. The results showed that nanomolar concentrations of probenecid prevented RSV replication in vitro and in vivo, suggesting its potential as a prophylactic and chemotherapeutic agent for RSV.
RNA viruses like SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV) are dependent on host genes for replication. We investigated if probenecid, an FDA-approved and safe urate-lowering drug that inhibits organic anion transporters (OATs) has prophylactic or therapeutic efficacy to inhibit RSV replication in three epithelial cell lines used in RSV studies, i.e., Vero E6 cells, HEp-2 cells, and in primary normal human bronchoepithelial (NHBE) cells, and in BALB/c mice. The studies showed that nanomolar concentrations of all probenecid regimens prevent RSV strain A and B replication in vitro and RSV strain A in vivo, representing a potential prophylactic and chemotherapeutic for RSV.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available